Julia Behnke | CEO and Co-Founder
ingineeon | advanced immunotherapeutics

Julia has been researching on immune proteins already during her PhD at a leading hospital in the US. Afterwards Julia was involved in development of various therapeutics from preclinics up to clinical and market access strategy development in the industry. After combining this expertise with economic know-how in her executive MBA in Innovation and Business Creation studies, Julia has built up ingineeon, a biotech spin-off from the Technical University of Munich. ingineeon´s pipeline comprises several first-in-class cytokine-based immunotherapeutics, one cytokine-based platform technology for advanced cell therapies and one enabling platform biotechnology for production of proteins in a non-standard format.